BEAM
Price
$27.53
Change
-$0.86 (-3.03%)
Updated
Jul 17 closing price
Capitalization
2.83B
24 days until earnings call
Intraday BUY SELL Signals
OCGN
Price
$1.36
Change
-$0.01 (-0.73%)
Updated
Jul 17 closing price
Capitalization
460.39M
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs OCGN

BEAM vs OCGN Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. OCGN commentary
Jul 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and OCGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2026
Stock price -- (BEAM: $27.53 vs. OCGN: $1.36)
Brand notoriety: BEAM and OCGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 58% vs. OCGN: 37%
Market capitalization -- BEAM: $2.83B vs. OCGN: $460.39M
BEAM [@Biotechnology] is valued at $2.83B. OCGN’s [@Biotechnology] market capitalization is $460.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $123.26B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileOCGN’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • OCGN’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than OCGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 4 TA indicator(s) are bullish while OCGN’s TA Score has 3 bullish TA indicator(s).

  • BEAM’s TA Score: 4 bullish, 5 bearish.
  • OCGN’s TA Score: 3 bullish, 8 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than OCGN.

Price Growth

BEAM (@Biotechnology) experienced а -15.76% price change this week, while OCGN (@Biotechnology) price change was -7.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.96%. For the same industry, the average monthly price growth was +4.20%, and the average quarterly price growth was +1909.86%.

Reported Earning Dates

BEAM is expected to report earnings on Aug 11, 2026.

OCGN is expected to report earnings on Jul 31, 2026.

Industries' Descriptions

@Biotechnology (-3.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.83B) has a higher market cap than OCGN($460M). OCGN YTD gains are higher at: 0.741 vs. BEAM (-0.685). OCGN has higher annual earnings (EBITDA): -64.04M vs. BEAM (-349.25M). BEAM has more cash in the bank: 1.21B vs. OCGN (31.9M). OCGN has less debt than BEAM: OCGN (33.3M) vs BEAM (251M). BEAM has higher revenues than OCGN: BEAM (164M) vs OCGN (4.47M).
BEAMOCGNBEAM / OCGN
Capitalization2.83B460M616%
EBITDA-349.25M-64.04M545%
Gain YTD-0.6850.741-93%
P/E RatioN/AN/A-
Revenue164M4.47M3,673%
Total Cash1.21B31.9M3,799%
Total Debt251M33.3M754%
FUNDAMENTALS RATINGS
BEAM vs OCGN: Fundamental Ratings
BEAM
OCGN
OUTLOOK RATING
1..100
8144
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
84
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
93100
PRICE GROWTH RATING
1..100
5857
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5018

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (27) in the null industry is somewhat better than the same rating for OCGN (84). This means that BEAM’s stock grew somewhat faster than OCGN’s over the last 12 months.

BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as OCGN (100). This means that BEAM’s stock grew similarly to OCGN’s over the last 12 months.

BEAM's SMR Rating (93) in the null industry is in the same range as OCGN (100). This means that BEAM’s stock grew similarly to OCGN’s over the last 12 months.

OCGN's Price Growth Rating (57) in the null industry is in the same range as BEAM (58). This means that OCGN’s stock grew similarly to BEAM’s over the last 12 months.

OCGN's P/E Growth Rating (100) in the null industry is in the same range as BEAM (100). This means that OCGN’s stock grew similarly to BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMOCGN
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 23 days ago
76%
Bullish Trend 25 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 3 days ago
64%
Bearish Trend 1 day ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signal:
Gain/Loss:
OCGN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SLAFX39.56N/A
N/A
DWS Latin America Equity S
MFADX28.60N/A
N/A
Cromwell Long Short Investor
JUSQX22.09N/A
N/A
JPMorgan US Small Company R4
TIBAX37.65-0.13
-0.34%
Thornburg Investment Income Builder A
SLVRX43.15-0.24
-0.55%
Columbia Select Large Cap Value R

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-3.03%
CRSP - BEAM
72%
Closely correlated
-1.63%
PRME - BEAM
63%
Loosely correlated
-2.80%
EDIT - BEAM
62%
Loosely correlated
+3.47%
NTLA - BEAM
59%
Loosely correlated
-4.09%
AXON - BEAM
57%
Loosely correlated
-5.81%
More